Metástasis

Brain Tumor Market is Projected to Propel Humbly at a CAGR of 4.19% in the 7MM for the Study Period 2017-30, Says DelveInsight

Retrieved on: 
Wednesday, March 10, 2021

Some of the vital points from the Brain Tumor Market report:

Key Points: 
  • Some of the vital points from the Brain Tumor Market report:
    The marketed drugs in the Brain Tumor market landscape include Avastin (Genentech) and Temodar/Temodal (Merck).
  • Symptoms of a Brain Tumor can be general or specific and vary depending upon the location of the Brain Tumor.
  • A Brain Tumor can fall into two main groups, i.e., Primary Brain Tumor and Metastatic Brain Tumor, on the basis of the spread of the tumor cells.
  • The Brain Tumor market insights report offers historical as well as forecasted Brain Tumor epidemiology coverage in the 7MM from 2018 to 2030 segmented into:

Brain Tumor Market is Projected to Propel Humbly at a CAGR of 4.19% in the 7MM for the Study Period 2017-30, Says DelveInsight

Retrieved on: 
Wednesday, March 10, 2021

Some of the vital points from the Brain Tumor Market report:

Key Points: 
  • Some of the vital points from the Brain Tumor Market report:
    The marketed drugs in the Brain Tumor market landscape include Avastin (Genentech) and Temodar/Temodal (Merck).
  • Symptoms of a Brain Tumor can be general or specific and vary depending upon the location of the Brain Tumor.
  • A Brain Tumor can fall into two main groups, i.e., Primary Brain Tumor and Metastatic Brain Tumor, on the basis of the spread of the tumor cells.
  • The Brain Tumor market insights report offers historical as well as forecasted Brain Tumor epidemiology coverage in the 7MM from 2018 to 2030 segmented into:

AHN Cancer Institute Opens Genomics Facility Offering Patients Next-Generation Gene Sequencing to Guide Treatment Decisions

Retrieved on: 
Tuesday, March 9, 2021

The Clinical Genomics Laboratory will provide next-generation gene sequencing based on blood or tumor samples from patients with metastatic (late-stage) cancer, and a variety of common early-stage cancers including breast, colon and lung cancer.

Key Points: 
  • The Clinical Genomics Laboratory will provide next-generation gene sequencing based on blood or tumor samples from patients with metastatic (late-stage) cancer, and a variety of common early-stage cancers including breast, colon and lung cancer.
  • "The advent of genomic testing and targeted therapies over the past several years has changed the face of cancer treatment," said David Bartlett, MD , chair, AHN Cancer Institute.
  • The growth of cancer cells is fueled by genetic abnormalities, such as malfunction of genes that prevent cancer, or that spark the growth of cancer cells.
  • AHN also has a formal affiliation with the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, one of the nation's 41 comprehensive cancer centers designated by the National Cancer Institute, for research, medical education and clinical services.

CNS Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference

Retrieved on: 
Thursday, March 4, 2021

HOUSTON, March 4, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals will present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021.

Key Points: 
  • HOUSTON, March 4, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals will present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021.
  • In addition to the presentation, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
  • For more information about the conference, please visit the conference website here .
  • CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system.

Lantheus Announces Publication of PyL™ (18F-DCFPyL) Results from Pivotal Studies

Retrieved on: 
Monday, March 1, 2021

The OSPREY trial data highlighted the high positive predictive value, negative predictive value and specificity of PyL in staging high-risk patients.

Key Points: 
  • The OSPREY trial data highlighted the high positive predictive value, negative predictive value and specificity of PyL in staging high-risk patients.
  • We believe PyL has the potential to play an important role in transforming the management of men with high-risk, recurrent or metastatic prostate cancer.
  • The key secondary endpoint in the trial was the percent of subjects with a change in intended prostate cancer treatment due to PyL imaging results.
  • In the key secondary endpoint, 63.9% of patients had a change in intended prostate cancer treatment following review of PyL imaging results.

Loki Therapeutics to Present at BIO CEO & Investor Digital Conference

Retrieved on: 
Thursday, February 11, 2021

Loki Therapeutics is an immuno oncology company that is developing a new generation of cancer therapeutics that efficiently deliver childhood recall antigens to tumor cells with genetically attenuated bacterial vectors.

Key Points: 
  • Loki Therapeutics is an immuno oncology company that is developing a new generation of cancer therapeutics that efficiently deliver childhood recall antigens to tumor cells with genetically attenuated bacterial vectors.
  • Loki is currently advancing AWAKE-LM-TT as a potential treatment for metastatic pancreatic cancer, as well as metastatic ovarian cancer.
  • Loki is also pursuing additional development programs based on other childhood vaccines, including polio (AWAKE-LM-PV) and mumps.
  • For more information on Loki Therapeutics please visit www.lokitx.com .

Kanazawa University research: Going the distance--insights into how cancer cells spread

Retrieved on: 
Monday, February 8, 2021

Genetic mutations found only in some of these cells are known to aid with the spread and progression of cancer.

Key Points: 
  • Genetic mutations found only in some of these cells are known to aid with the spread and progression of cancer.
  • To replicate polyclonal metastasis, AP cells were then co-transplanted with AKTP cells, and voila, both cell types indeed moved into the livers.
  • Instead, when AP cells were injected into the blood (without prior exposure to the AKTP cells) they could not metastasize.
  • Next, AKTP cells within the liver tumors were killed to see how closely that affected the AP cells.

Kanazawa University research: Going the distance--insights into how cancer cells spread

Retrieved on: 
Monday, February 8, 2021

Genetic mutations found only in some of these cells are known to aid with the spread and progression of cancer.

Key Points: 
  • Genetic mutations found only in some of these cells are known to aid with the spread and progression of cancer.
  • To replicate polyclonal metastasis, AP cells were then co-transplanted with AKTP cells, and voila, both cell types indeed moved into the livers.
  • Instead, when AP cells were injected into the blood (without prior exposure to the AKTP cells) they could not metastasize.
  • Next, AKTP cells within the liver tumors were killed to see how closely that affected the AP cells.

Metavivor Announces Six Additional Metastatic Breast Cancer Research Awards for 2020

Retrieved on: 
Thursday, February 4, 2021

ANNAPOLIS, Md., Feb. 4, 2021 /PRNewswire-PRWeb/ -- METAvivor Research and Support Inc., a non-profit organization dedicated to funding research for Stage IV metastatic breast cancer (MBC), announces six additional grant awards, bringing the 2020 grant award total to $4,400,000.

Key Points: 
  • ANNAPOLIS, Md., Feb. 4, 2021 /PRNewswire-PRWeb/ -- METAvivor Research and Support Inc., a non-profit organization dedicated to funding research for Stage IV metastatic breast cancer (MBC), announces six additional grant awards, bringing the 2020 grant award total to $4,400,000.
  • In the US, only 2-5% of all cancer research funds are dedicated to Stage IV cancer research yet 98% of all breast cancer deaths are caused by a metastasis.
  • METAvivor sends a "thank you" to the donors, fundraisers, research partners, sponsors and the metastatic breast cancer community for helping reach the research goal for 2020.
  • METAvivor is the only national organization with a peer-reviewed grant program aimed at exclusively funding metastatic breast cancer research, and 100% of all donations go to fund research.

Propanc Biopharma Appoints Belen Toledo to Evaluate Impact of Proenzyme Therapy on Tumor Microenvironment

Retrieved on: 
Thursday, January 28, 2021

Propanc Biopharma, Inc. (OTCQB: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Company appointed Ms. Belen Toledo MSc., a biotechnologist specializing in cell regenerative medicine, to evaluate the impact of proenzyme therapy on the tumor microenvironment.

Key Points: 
  • Propanc Biopharma, Inc. (OTCQB: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Company appointed Ms. Belen Toledo MSc., a biotechnologist specializing in cell regenerative medicine, to evaluate the impact of proenzyme therapy on the tumor microenvironment.
  • A pre-metastatic tumor niche is an environment in a secondary organ conducive to the metastasis (spreading) of a primary tumor.
  • Such a niche provides favorable conditions for growth, and eventually metastasis, in an otherwise foreign and hostile environment for the primary tumor cells.
  • The application of 3D tumor models on-a-chip will allow us to faithfully recreate tumor heterogeneity and stroma-tumor interactions.